Home/Pipeline/WVE-003

WVE-003

Huntington's Disease

Phase 1b/2aActive - SELECT-HD trial

Key Facts

Indication

Huntington's Disease

Phase

Phase 1b/2a

Status

Active - SELECT-HD trial

Company

WaVe Life Sciences

About WaVe Life Sciences

Wave Life Sciences is a clinical-stage biotech focused on developing stereopure oligonucleotide therapeutics via its proprietary PRISM® platform. The company has built a diversified pipeline targeting both rare genetic disorders and common diseases, with key programs in obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), Duchenne muscular dystrophy, and Huntington's disease. Its strategy combines validated human genetics, a multi-modal RNA-targeting approach, and stereochemistry control to aim for best-in-class efficacy and tolerability. Recent positive interim Phase 1 data in obesity and strategic moves to accelerate its RNA editing portfolio underscore its momentum.

View full company profile

Therapeutic Areas

Obesity Genetic Disorders Neuromuscular Diseases Neurodegenerative Diseases

Other Huntington's Disease Drugs

Drug	Company	Phase	Status
Huntington's Disease Program	Rumi Scientific	Pre-clinical	Active
SOM3355	SOM Biotech	Phase 3	Active
LETI-101	ElevateBio	Preclinical	Active
Somatic Expansion Inhibitor Program	LoQus23 Therapeutics	Preclinical	Active
Preclinical Program	Excision BioTherapeutics	Preclinical	Active
NA-841	Biomed	Phase 2A	Active
T3D-959 (Future)	T3D Therapeutics	Pre-clinical / Research	Active
HD mAb Therapy	HD Immune	Pre-clinical	Active
TT-P34	Teitur Trophics	Pre-clinical	Active
INT41	Vybion	Pre-clinical	Active
Huntington's Program	reMYND	Pre-clinical	Active
Poseido (RO7435846)	Roche	Phase III	Active